What’s the current market cap for Novo Nordisk stock?

Novo Nordisk (NVO) has a market cap of $194bn as of June 06, 2026.

What is the P/E ratio for Novo Nordisk stock?

The price to earnings (P/E) ratio for Novo Nordisk (NVO) stock is 10.17 as of June 06, 2026.

Does Novo Nordisk stock pay dividends?

Yes, the Novo Nordisk (NVO) stock pays dividends to shareholders. As of June 06, 2026, the dividend rate is $1.28523 and the yield is 4.07%. Novo Nordisk has a payout ratio of 42.47% on a trailing twelve-month basis.

When is the next Novo Nordisk dividend payment date?

The next Novo Nordisk (NVO) dividend payment date is unconfirmed.

What is the beta indicator for Novo Nordisk?

Novo Nordisk (NVO) has a beta rating of 0.35. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy Novo Nordisk stock | $NVO Share Price

13:30

15:10

16:45

18:25

20:00

About Novo Nordisk

With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Ticker

$NVO

Sector

Health

Primary listing

NYSE

Employees

67,900

Headquarters

Bagsvaerd, Denmark

Website

www.novonordisk.com

Novo Nordisk Metrics

BasicAdvanced

$194bn

10.17

$4.23

0.35

$1.29

4.07%

What the Analysts think about Novo Nordisk

Analyst ratings (Buy, Hold, Sell) for Novo Nordisk stock.

Bulls say / Bears say

Novo Nordisk introduced an oral Wegovy pill for self-paying patients in the U.S. at $149 per month, expanding its obesity treatment lineup and improving patient access.

The collaboration between Novo Nordisk and OpenAI to implement AI across drug discovery, production, and commercial areas is expected to speed up development and drive efficiency.

Analysts estimate that annual sales of GLP-1 weight-loss drugs could surpass $100 billion in the next decade, pointing to Novo Nordisk’s solid long-term growth prospects in the obesity and diabetes sectors.

Up to 1.5 million U.S. patients may be taking compounded, unapproved versions of Novo Nordisk’s GLP-1 drugs, threatening its branded obesity and diabetes business.

Novo Nordisk has admitted it is trailing Eli Lilly in the weight-loss drug market, underlining rising competitive challenges from rivals such as Lilly’s recently approved Foundayo.

Novo Nordisk’s oral Wegovy pill is available only for self-pay patients at $149 per month, indicating insurer reluctance may hinder wider adoption and limit volume growth.

Data summarised monthly by Lightyear AI. Last updated on 1 Jun 2026.

Novo Nordisk Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

Novo Nordisk Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $NVO

Capital at risk

Market closedADR

Upcoming events

No upcoming events